Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study

Anat Achiron; Mathilda Mandel; Sapir Dreyer-Alster; Gil Harari; Mark Dolev; Shay Menascu; David Magalashvili; Shlomo Flechter; Uri Givon; Diana Guber; Polina Sonis; Rina Zilkha-Falb; Michael Gurevich

doi:10.1016/j.jneuroim.2021.577746

Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study

Anat Achiron, Mathilda Mandel, Sapir Dreyer-Alster, Gil Harari, Mark Dolev, Shay Menascu, David Magalashvili, Shlomo Flechter, Uri Givon, Diana Guber, Polina Sonis, Rina Zilkha-Falb, Michael Gurevich

School of Public Health

Research output: Contribution to journal › Article › peer-review

Abstract

Appropriate immune response following COVID-19 vaccination is important in the context of disease-modifying treatments (DMTs). In a prospective cross-sectional study, we determined SARS-COV-2 IgG response up to 6 months following PfizerBNT162b2 vaccination in 414 multiple sclerosis (MS) patients and 89 healthy subjects. Protective response was demonstrated in untreated MS patients (N = 76, 100%), treated with Cladribine (N = 48, 100%), Dimethyl fumarate (N = 35, 100%), Natalizumab (N = 32, 100%), and Teriflunomide (N = 39, 100%), similarly to healthy subjects (N = 89, 97.8%). Response was decreased in Fingolimod (N = 42, 9.5%), Ocrelizumab (N = 114, 22.8%) and Alemtuzumab (N = 22, 86.4%) treated patients. IgG response can help tailor adequate vaccine guidelines for MS patients under various DMTs.

Original language	English
Article number	577746
Journal	Journal of Neuroimmunology
Volume	361
DOIs	https://doi.org/10.1016/j.jneuroim.2021.577746
State	Published - 15 Dec 2021

Bibliographical note

Publisher Copyright:
© 2021 Elsevier B.V.

Keywords

COVID-19
Disease modifying treatments
Humoral immunity
IgG antibody
Multiple sclerosis
Vaccination

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Neurology
Clinical Neurology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jneuroim.2021.577746

Cite this

Achiron, A., Mandel, M., Dreyer-Alster, S., Harari, G., Dolev, M., Menascu, S., Magalashvili, D., Flechter, S., Givon, U., Guber, D., Sonis, P., Zilkha-Falb, R., & Gurevich, M. (2021). Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study. Journal of Neuroimmunology, 361, Article 577746. https://doi.org/10.1016/j.jneuroim.2021.577746

@article{1e3984ea05c4479c9009909b41069e8a,

title = "Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study",

abstract = "Appropriate immune response following COVID-19 vaccination is important in the context of disease-modifying treatments (DMTs). In a prospective cross-sectional study, we determined SARS-COV-2 IgG response up to 6 months following PfizerBNT162b2 vaccination in 414 multiple sclerosis (MS) patients and 89 healthy subjects. Protective response was demonstrated in untreated MS patients (N = 76, 100%), treated with Cladribine (N = 48, 100%), Dimethyl fumarate (N = 35, 100%), Natalizumab (N = 32, 100%), and Teriflunomide (N = 39, 100%), similarly to healthy subjects (N = 89, 97.8%). Response was decreased in Fingolimod (N = 42, 9.5%), Ocrelizumab (N = 114, 22.8%) and Alemtuzumab (N = 22, 86.4%) treated patients. IgG response can help tailor adequate vaccine guidelines for MS patients under various DMTs.",

keywords = "COVID-19, Disease modifying treatments, Humoral immunity, IgG antibody, Multiple sclerosis, Vaccination",

author = "Anat Achiron and Mathilda Mandel and Sapir Dreyer-Alster and Gil Harari and Mark Dolev and Shay Menascu and David Magalashvili and Shlomo Flechter and Uri Givon and Diana Guber and Polina Sonis and Rina Zilkha-Falb and Michael Gurevich",

note = "Publisher Copyright: {\textcopyright} 2021 Elsevier B.V.",

year = "2021",

month = dec,

day = "15",

doi = "10.1016/j.jneuroim.2021.577746",

language = "English",

volume = "361",

journal = "Journal of Neuroimmunology",

issn = "0165-5728",

publisher = "Elsevier",

}

Achiron, A, Mandel, M, Dreyer-Alster, S, Harari, G, Dolev, M, Menascu, S, Magalashvili, D, Flechter, S, Givon, U, Guber, D, Sonis, P, Zilkha-Falb, R & Gurevich, M 2021, 'Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study', Journal of Neuroimmunology, vol. 361, 577746. https://doi.org/10.1016/j.jneuroim.2021.577746

TY - JOUR

T1 - Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination

T2 - Up to 6 months cross-sectional study

AU - Achiron, Anat

AU - Mandel, Mathilda

AU - Dreyer-Alster, Sapir

AU - Harari, Gil

AU - Dolev, Mark

AU - Menascu, Shay

AU - Magalashvili, David

AU - Flechter, Shlomo

AU - Givon, Uri

AU - Guber, Diana

AU - Sonis, Polina

AU - Zilkha-Falb, Rina

AU - Gurevich, Michael

PY - 2021/12/15

Y1 - 2021/12/15

N2 - Appropriate immune response following COVID-19 vaccination is important in the context of disease-modifying treatments (DMTs). In a prospective cross-sectional study, we determined SARS-COV-2 IgG response up to 6 months following PfizerBNT162b2 vaccination in 414 multiple sclerosis (MS) patients and 89 healthy subjects. Protective response was demonstrated in untreated MS patients (N = 76, 100%), treated with Cladribine (N = 48, 100%), Dimethyl fumarate (N = 35, 100%), Natalizumab (N = 32, 100%), and Teriflunomide (N = 39, 100%), similarly to healthy subjects (N = 89, 97.8%). Response was decreased in Fingolimod (N = 42, 9.5%), Ocrelizumab (N = 114, 22.8%) and Alemtuzumab (N = 22, 86.4%) treated patients. IgG response can help tailor adequate vaccine guidelines for MS patients under various DMTs.

AB - Appropriate immune response following COVID-19 vaccination is important in the context of disease-modifying treatments (DMTs). In a prospective cross-sectional study, we determined SARS-COV-2 IgG response up to 6 months following PfizerBNT162b2 vaccination in 414 multiple sclerosis (MS) patients and 89 healthy subjects. Protective response was demonstrated in untreated MS patients (N = 76, 100%), treated with Cladribine (N = 48, 100%), Dimethyl fumarate (N = 35, 100%), Natalizumab (N = 32, 100%), and Teriflunomide (N = 39, 100%), similarly to healthy subjects (N = 89, 97.8%). Response was decreased in Fingolimod (N = 42, 9.5%), Ocrelizumab (N = 114, 22.8%) and Alemtuzumab (N = 22, 86.4%) treated patients. IgG response can help tailor adequate vaccine guidelines for MS patients under various DMTs.

KW - COVID-19

KW - Disease modifying treatments

KW - Humoral immunity

KW - IgG antibody

KW - Multiple sclerosis

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=85116922368&partnerID=8YFLogxK

U2 - 10.1016/j.jneuroim.2021.577746

DO - 10.1016/j.jneuroim.2021.577746

M3 - Article

C2 - 34655991

AN - SCOPUS:85116922368

SN - 0165-5728

VL - 361

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

M1 - 577746

ER -

Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this